Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Behaviors and Mental Disorders

Nervous System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Symptoms and General Pathology

Heart and Blood Diseases

Immune System Diseases

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Diabetes Mellitus

Depressive Disorder

Dementia

Kidney Diseases

Mental Disorders

Lung Diseases, Obstructive

Pulmonary Disease, Chronic Obstructive

Depression

Obesity

Heart Failure

Asthma

Stroke

Atrial Fibrillation

Coronary Artery Disease

Myocardial Ischemia

Coronary Disease

Hypertension

Heart Diseases

Ischemia

Arthritis

Epilepsy

Lung Diseases

Peripheral Arterial Disease

Peripheral Vascular Diseases

Arthritis, Rheumatoid

Ischemic Stroke

Renal Insufficiency, Chronic

Renal Insufficiency

Vascular Diseases

Psychotic Disorders

Arrhythmias, Cardiac

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Respiratory Tract Diseases

Brain Diseases

Central Nervous System Diseases

Chronic Disease

Disease Attributes

Atherosclerosis

Arteriosclerosis

Arterial Occlusive Diseases

Cerebrovascular Disorders

Chronic Graft Versus Host Disease

There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.

Dr Mohammed Kamran

Mohammed Kamran, PhD

Health inequality and genetic disparity are a significant issue in the United Kingdom (UK).

This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations.

The vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that participated in the drug licencing clinical trials. A consequence of this is that drugs are licensed for use in real-world general patient populations where the clinical trial results are simply not statistically significant to specifically demonstrate efficacy or safety in populations that were either absent or under-represented in the drug registration clinical trials. When these facts are considered alongside data that supports significant under-reporting of adverse events in the real-world setting within the UK (and globally, e.g the USA and Europe), it highlights that pharmacovigilance systems are unable to capture drug effectiveness and safety data in a manner that can reasonably assure appropriate prescribing in the wider patient populations.

This large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK.

The goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.

This multi-centre real-world study will recruit patients across different National Health Service (NHS) sites based in England, where the overall patient population demographic profile is sufficiently variable to allow for meaningful representation of different ethnicities in the analysis of pooled data-sets.

The study addresses the issue of health inequality and genetic disparity in the United Kingdom (UK) by recruiting up to 200,000 patients primarily from the three main ethnic groups in the UK; namely White (Caucasian), African-Caribbean (Black), and South Asian (Asian) populations on a 1:1:1 ratio.

Biological samples, medical records, alongside specific questionnaires will be used in data analyses to help identify treatment failures in different populations for the 19 disease areas under investigation, which are a significant cause of morbidity and mortality in the UK.

Analysis of patient populations may provide real-world evidence around disease prevalence between and within different ethnic groups. The data may also support hypothesis driven genetic analysis to identify putative bio-markers associated with treatment failure.

Data from this study will be published, and findings could better inform clinical practice in the management of diseases that cause significant poor health and death in the different populations that represent the UK.

Saliva. Where practical, blood or other biological samples may also be voluntarily provided by the patient.

EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality

EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population

Identify ethnic disparities in treatment failures for any of the 19 disease states under investigation. The primary outcome is treatment failure, as measured by the discontinuation of a treatment regimen by a clinician in the absence of the cure of the disease, for the most common treatment in each of the 19 diseases.

Identifying ethnic disparities in disease incidence. The corresponding secondary outcome measure for this is, for each of the 19 diseases under consideration, the diagnosis of the disease. We will use time to diagnosis to examine ethnic disparities in incidence.

Another secondary outcome is identifying candidate genetic variants that may underpin observed disparities in treatment failure, for treatments in the 19 diseases under consideration. The corresponding secondary outcome measures used for this are genotypes as identified through whole genome sequencing (WGS) of patient saliva or peripheral blood that are associated with the phenotypes corresponding to the treatment failure previously described as the primary outcome measure.

Future Genetics Limited

Neoplasms

Wounds and Injuries

Diseases and Abnormalities at or Before Birth

Eye Diseases

Blood and Lymph Conditions

Infections

Multiple Sclerosis

Sclerosis

Syndrome

Myasthenia Gravis

Muscle Weakness

Brain Injuries

Brain Injuries, Traumatic

Spinal Cord Injuries

Motor Neuron Disease

Amyotrophic Lateral Sclerosis

Paresis

Muscular Dystrophies

Graves Disease

Asthenia

Hemorrhagic Stroke

Ehlers-Danlos Syndrome

Guillain-Barre Syndrome

Autoimmune Diseases

Demyelinating Autoimmune Diseases, CNS

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Craniocerebral Trauma

Trauma, Nervous System

Spinal Cord Diseases

Neurodegenerative Diseases

Neuromuscular Diseases

TDP-43 Proteinopathies

Proteostasis Deficiencies

Metabolic Diseases

Atrophy

Muscular Diseases

Muscular Disorders, Atrophic

Genetic Diseases, Inborn

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Neuromuscular Junction Diseases

Exophthalmos

Orbital Diseases

Goiter

Thyroid Diseases

Endocrine System Diseases

Hyperthyroidism

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Hematologic Diseases

Congenital Abnormalities

Skin Abnormalities

Skin Diseases

Skin Diseases, Genetic

Rheumatic Diseases

Collagen Diseases

Connective Tissue Diseases

Polyradiculoneuropathy

Polyneuropathies

Peripheral Nervous System Diseases

Communicable Diseases

Post-Infectious Disorders

Muscular Dystrophy

Primary Lateral Sclerosis

Acute Graft Versus Host Disease

Ehlers-Danlos Syndromes

* Individuals aged 18 years to 55 years.
* Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments.
* Regular users of beauty products.
* Able to understand and communicate in the language of the study.

Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.

Use of Rare Beauty makeup products

Emily Rosario, PhD

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.

Individuals with upper extremity disabilities face unique challenges when it comes to using beauty products. These disabilities can include conditions such as limb loss, limited mobility, or dexterity impairments, which can significantly impact their ability to engage in self-care and beauty routines. The accessibility of beauty products is crucial to ensure that individuals with upper extremity disabilities have equal opportunities to participate in activities that promote self-expression and confidence.

Research in the field of accessible design has highlighted the importance of inclusive product development across various industries, including cosmetics and personal care. However, limited attention has been given specifically to beauty products and their usability for individuals with upper extremity disabilities.

To address this gap, studies are being conducted to assess the accessibility of beauty products and identify potential barriers and solutions. These studies typically examine factors such as packaging design, ergonomics of product applicators, ease of grip, and maneuverability. By understanding the specific challenges faced by individuals with upper extremity disabilities, researchers can propose modifications and design considerations that enhance accessibility.

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

Exploring Accessible Beauty: A Study on Enhancing Beauty Product Accessibility for Individuals With Upper Extremity Deficits

It is a validated self-reported instrument to assess packaging of the makeup. A few questions will focus on shape of the cap, length of the wand, shape of the doe foot, finish of the components, how it affects grip, and weight of the component/applicator. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

Participants will complete questionnaires that assess their demographics, disability characteristics, and previous experiences with beauty products.

Participants will evaluate the beauty products based on predefined criteria, including ease of grip, maneuverability, packaging design, and product applicators. They will document their experiences, challenges faced, and any suggestions for improvements. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

Participants will assess changes in their perceptions and experiences with the beauty products. This will include questions about satisfaction, usability, and any perceived improvements in accessibility. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

Casa Colina Hospital and Centers for Healthcare

Executive Director

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality	NCT03987633	Atrial Fibrilla... Coronary Heart ... Cardiovascular ... Heart Failure Hypertension Peripheral Arte... Stroke, Ischemi... Asthma Chronic Obstruc... Obesity Cancer Chronic Kidney ... Diabetes Mellit... Dementia Depression Epilepsy Mental Health D... Rheumatoid Arth... Blood Pressure		6 Years -	Future Genetics Limited
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits	NCT05945784	Stroke, Ischemi... Stroke Hemorrha... Stroke (CVA) or... Stroke, Acute Traumatic Brain... SCI - Spinal Co... Ehlers-Danlos S... Lupus Erythemat... Guillain-Barre ... Multiple Sclero... Myasthenia Grav... Amyotrophic Lat... Graves Disease Muscular Dystro...	Use of Rare Bea...	18 Years - 55 Years	Casa Colina Hospital and Centers for Healthcare

Spots Global Cancer Trial Database for stroke, ischemic